Rare Disease Trial, Recruiting NCT06677866 Sponsor: Bambino Gesù Hospital and Research Institute Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT06677866
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

For participants with Fragile X Syndrome (FXS):

Who might be able to join this trial:

  • The participant has been diagnosed with Fragile X Syndrome (FXS), confirmed by a genetic test.
  • The participant is between 13 and 19 years old.
  • The participant can communicate verbally using sentences (enough to take part in group activities).
  • The participant has difficulties with everyday living skills, as measured by a standard assessment called VABS II, with a score below 70.
  • A parent or guardian has given written consent for their child to participate and for their data to be used.

Who may not be able to join:

  • The participant has serious problems with their vision or hearing.
  • The participant has been diagnosed with epilepsy or has had seizures that require medication.
  • The participant is currently receiving another non-medication-based therapy or treatment.
  • The participant's medication has been changed in the last 3 months.
  • The participant has health issues or challenging behaviours that could disrupt group activities, based on a specific behaviour checklist score (confirm with trial site).
  • The participant has an IQ score below 40, as measured by a specific intelligence test called the Leiter-3.
  • The participant has very severely limited everyday living skills, with a VABS II score below 20.

For participants with Autism Spectrum Disorder (ASD):

Who might be able to join this trial:

  • The participant has been diagnosed with Autism Spectrum Disorder (ASD), confirmed through recognised professional assessment tools.
  • The participant is between 13 and 19 years old.
  • The participant can communicate verbally using sentences (enough to take part in group activities).
  • The participant has difficulties with everyday living skills, as measured by a standard assessment called VABS II, with a score below 70.
  • A parent or guardian has given written consent for their child to participate and for their data to be used.

Who may not be able to join:

  • The participant has serious problems with their vision or hearing.
  • The participant has been identified as having a specific genetic condition associated with autism, such as Tuberous Sclerosis, Fragile X Syndrome, Rett Syndrome, or certain chromosomal differences (confirm with trial site for full list).
  • The participant has been diagnosed with epilepsy or has had seizures that require medication.
  • The participant is currently receiving another non-medication-based therapy or treatment.
  • The participant's medication has been changed in the last 3 months.
  • The participant has health issues or challenging behaviours that could disrupt group activities, based on a specific behaviour checklist score (confirm with trial site).
  • The participant has an IQ score below 40, as measured by a specific intelligence test called the Leiter-3.
  • The participant has very severely limited everyday living skills, with a VABS II score below 20.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paolo Alfieri, MD, PhD, Bambino Gesù Children's Hospital

Phone: 06/68597009

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bambino Gesù Hospital and Research Institute
Registry
ClinicalTrials.gov
Start date
1 September 2022
Est. completion
15 September 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Global Clinical Impression - Severity Scale (CGI-S)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov